BIOMEA FUSION INC (BMEA) Stock Price, Quote, News and Overview
NASDAQ:BMEA - Nasdaq - US09077A1060 - Common Stock - Currency: USD
BMEA Quote, Performance and Key Statistics
BIOMEA FUSION INC
NASDAQ:BMEA (1/23/2025, 11:34:58 AM)
4.24
-0.08 (-1.85%)
The current stock price of BMEA is 4.24 USD. In the past month the price increased by 5.88%. In the past year, price decreased by -73.8%.
BMEA Latest News, Press Releases and Analysis
Biomea Fusion to Become a Diabetes & Obesity Medicines Company
Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study
Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company...
Commit To Purchase Biomea Fusion At $2.50, Earn 26% Using Options
BMEA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.83 | 300.63B | ||
| AMGN | AMGEN INC | 14.26 | 147.28B | ||
| GILD | GILEAD SCIENCES INC | 20.92 | 115.52B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 845.55 | 111.05B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.06 | 75.21B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.43B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.85B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.01B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.48B | ||
| NTRA | NATERA INC | N/A | 22.68B | ||
| BIIB | BIOGEN INC | 8.68 | 20.66B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.36B |
Related screens
About BMEA
Company Profile
Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. The company is headquartered in Redwood City, California and currently employs 107 full-time employees. The company went IPO on 2021-04-16. The firm is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The firm is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Its lead product candidate, BMF-219, is designed to be an oral, potent, and selective covalent inhibitor of menin, built from its FUSION System. The company is developing BMF-219 for the treatment of menin regulated or dependent diseases, such as type 1 and type 2 diabetes as well as subtypes of liquid and solid tumors. Its second development candidate, BMF-500, a covalent inhibitor of activating mutations of the FMS-like tyrosine kinase 3 (FLT3).
Company Info
BIOMEA FUSION INC
900 Middlefield Road, 4th Floor
Redwood City CALIFORNIA US
Employees: 112
Company Website: https://www.biomeafusion.com/
Investor Relations: http://investors.biomeafusion.com
Phone: 16509809099
BMEA FAQ
What is the price of BMEA?
The current price of BMEA is 4.24 USD.
What is the symbol for BIOMEA FUSION INC?
The exchange symbol of BIOMEA FUSION INC is BMEA and it is listed on the Nasdaq exchange.
On which exchange is BMEA listed?
BMEA is listed on the Nasdaq exchange.
Is BMEA a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for BMEA, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of BMEA.
Does BMEA pay dividends?
BMEA does not pay a dividend.
What is the Price/Earnings (PE) ratio of BMEA?
BMEA does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.01).
What is the Short Interest ratio of BMEA?
The outstanding short interest for BMEA is 42.49% of its float.
BMEA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to BMEA. When comparing the yearly performance of all stocks, BMEA is a bad performer in the overall market: 98.42% of all stocks are doing better.
BMEA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BMEA. BMEA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
BMEA Financial Highlights
Over the last trailing twelve months BMEA reported a non-GAAP Earnings per Share(EPS) of -4.01. The EPS increased by -20.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -130.42% | ||
| ROE | -189.55% | ||
| Debt/Equity | 0 |
BMEA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 81% to BMEA. The Buy consensus is the average rating of analysts ratings from 15 analysts.